The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
TGF-β signaling and the fibrotic response
Leask, A., & Abraham, D. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-1273rev · Cited by 2,319
Biernacka, A., Dobaczewski, M., & Frangogiannis, N. G. (2011) · Growth Factors · doi:10.3109/08977194.2011.595714 · Cited by 1,161
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease
Willis, B. C., & Borok, Z. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00163.2007 · Cited by 1,042
Fichtner-Feigl, S., Strober, W., Kawakami, K., Puri, R. K., & Kitani, A. (2006) · Nature Medicine · doi:10.1038/nm1332 · Cited by 889
Barry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H. M., Oyasu, M., Mikels, A., Vaysberg, M., Ghermazien, H., Wai, C., et al. (2010) · Nature Medicine · doi:10.1038/nm.2208 · Cited by 870
Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., et al. (2008) · Nature Medicine · doi:10.1038/nm1685 · Cited by 823
Murine models of pulmonary fibrosis
Moore, B. B., & Hogaboam, C. M. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00313.2007 · Cited by 796
Wollin, L., Maillet, I., Quesniaux, V., Holweg, A., & Ryffel, B. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.208223 · Cited by 633
Sleijfer, S. (2001) · Chest · doi:10.1378/chest.120.2.617 · Cited by 611
Bleomycin: New Perspectives on the Mechanism of Action
Hecht, S. M. (2000) · Journal of Natural Products · doi:10.1021/np990549f · Cited by 559
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
Galm, U., Hager, M. H., Van Lanen, S. G., Ju, J., Thorson, J. S., & Shen, B. (2005) · Chemical Reviews · doi:10.1021/cr030117g · Cited by 556
Prognostic Implications of Physiologic and Radiographic Changes in Idiopathic Interstitial Pneumonia
Flaherty, K. R., Mumford, J. A., Murray, S., Kazerooni, E. A., Gross, B. H., Colby, T. V., Travis, W. D., Flint, A., Toews, G. B., Lynch, J. P., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200209-1112oc · Cited by 513
Activated bleomycin. A transient complex of drug, iron, and oxygen that degrades DNA.
Burger, R. M., Peisach, J., & Horwitz, S. B. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)68452-8 · Cited by 462
Mechanisms of bleomycin-induced lung damage
Hay, J., Shahzeidi, S., & Laurent, G. (1991) · Archives of Toxicology · doi:10.1007/bf02034932 · Cited by 389
Cumulative incidence of and predictive factors for lung cancer in IPF
OZAWA, Y., SUDA, T., NAITO, T., ENOMOTO, N., HASHIMOTO, D., FUJISAWA, T., NAKAMURA, Y., INUI, N., NAKAMURA, H., & CHIDA, K. (2009) · Respirology · doi:10.1111/j.1440-1843.2009.01547.x · Cited by 314
Modeling pulmonary fibrosis with bleomycin
Mouratis, M. A., & Aidinis, V. (2011) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328349ac2b · Cited by 311
Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis
Degryse, A. L., Tanjore, H., Xu, X. C., Polosukhin, V. V., Jones, B. R., McMahon, F. B., Gleaves, L. A., Blackwell, T. S., & Lawson, W. E. (2010) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00026.2010 · Cited by 311
Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease
Wang, Q., Usinger, W., Nichols, B., Gray, J., Xu, L., Seeley, T. W., Brenner, M., Guo, G., Zhang, W., Oliver, N., et al. (2011) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-4-4 · Cited by 278
Nucleic Acid Recognition by Metal Complexes of Bleomycin
Claussen, C. A., & Long, E. C. (1999) · Chemical Reviews · doi:10.1021/cr980449z · Cited by 276
A novel, orally active LPA 1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model
Swaney, J., Chapman, C., Correa, L., Stebbins, K., Bundey, R., Prodanovich, P., Fagan, P., Baccei, C., Santini, A., Hutchinson, J., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00828.x · Cited by 261
Strategies for treating idiopathic pulmonary fibrosis
du Bois, R. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2958 · Cited by 251
Ahluwalia, N., Shea, B. S., & Tager, A. M. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201403-0509pp · Cited by 235
Bleomycin: Revival of an old drug
Mir, L. M., Tounekti, O., & Orlowski, S. (1996) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(95)02101-9 · Cited by 227
Chemotherapy-induced lung disease
Limper, A. H. (2004) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(03)00123-0 · Cited by 206
Novel therapeutic approaches for pulmonary fibrosis
Datta, A., Scotton, C. J., & Chambers, R. C. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01247.x · Cited by 202
A review of current and novel therapies for idiopathic pulmonary fibrosis.
Rafii, R., Juarez, M. M., Albertson, T. E., & Chan, A. L. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2012.12.07 · Cited by 173
Cutroneo, K. R., White, S. L., Phan, S. H., & Ehrlich, H. P. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.20972 · Cited by 170
Saleh, D., Furukawa, K., Tsao, M. S., Maghazachi, A., Corrin, B., Yanagisawa, M., Barnes, P. J., & Giaid, A. (1997) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.16.2.9032126 · Cited by 165
Mouse Models of Bleomycin‐Induced Pulmonary Fibrosis
Walters, D. M., & Kleeberger, S. R. (2008) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph0546s40 · Cited by 152
Povirk, L. F., Han, Y., & Steighner, R. J. (1989) · Biochemistry · doi:10.1021/bi00440a016 · Cited by 150
Bleomycin lung toxicity: who are the patients with increased risk?
de Azambuja, E., Fleck, J. F., Batista, R. G., & Barreto, S. S. M. (2005) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2005.01.007 · Cited by 150
TAKITA, T., MURAOKA, Y., Nakatani, T., et al. (1978) · The Journal of Antibiotics · doi:10.7164/antibiotics.31.1073 · Cited by 147
Hisatomi, K., Mukae, H., Sakamoto, N., Ishimatsu, Y., Kakugawa, T., Hara, S., Fujita, H., Nakamichi, S., Oku, H., Urata, Y., et al. (2012) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-12-24 · Cited by 144
Mechanism of bleomycin action: studies
Burger, R. M., Peisach, J., & Horwitz, S. B. (1981) · Life Sciences · doi:10.1016/0024-3205(81)90153-3 · Cited by 142
The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury
Funke, M., Zhao, Z., Xu, Y., Chun, J., & Tager, A. M. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0155oc · Cited by 141
Inomata, M., Kamio, K., Azuma, A., Matsuda, K., Kokuho, N., Miura, Y., Hayashi, H., Nei, T., Fujita, K., Saito, Y., et al. (2014) · Respiratory Research · doi:10.1186/1465-9921-15-16 · Cited by 140
Palanivel, C., Gowrikumar, S., Manikandan, R., & Sudhandiran, G. (2013) · Toxicology Letters · doi:10.1016/j.toxlet.2013.03.009 · Cited by 136
Therapeutic Targeting of IL-4- and IL-13-Responsive Cells in Pulmonary Fibrosis
Jakubzick, C., Kunkel, S. L., Puri, R. K., & Hogaboam, C. M. (2004) · Immunologic Research · doi:10.1385/ir:30:3:339 · Cited by 118
Chen, T., Nie, H., Gao, X., Yang, J., Pu, J., Chen, Z., Cui, X., Wang, Y., Wang, H., & Jia, G. (2014) · Toxicology Letters · doi:10.1016/j.toxlet.2014.02.004 · Cited by 117
Gefitinib Prevents Bleomycin-induced Lung Fibrosis in Mice
Ishii, Y., Fujimoto, S., & Fukuda, T. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200509-1534oc · Cited by 111
Malouf, M. A., Hopkins, P. M.-A., Snell, G. I., & Glanville, A. R. (2011) · Respirology · doi:10.1111/j.1440-1843.2011.01955.x · Cited by 102
Angelini, D. J., Su, Q., Yamaji-Kegan, K., Fan, C., SKINNER, J. T., Poloczek, A., El‐Haddad, H., Cheadle, C., & Johns, R. A. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-1 · Cited by 102
VERMA, R. C., Kushwah, L., Gohel, D., Patel, M., Marvania, T., & Balakrishnan, S. (2013) · Pulmonary Medicine · doi:10.1155/2013/921724 · Cited by 95
Current and novel drug therapies for idiopathic pulmonary fibrosis
Maher, T. M., & Adamali, H. I. (2012) · Drug Design Development and Therapy · doi:10.2147/dddt.s29928 · Cited by 89
Bei, Y., Hua-Huy, T., Duong‐Quy, S., Nguyen, V.-H., Chen, W., Nicco, C., Batteux, F., & Dinh‐Xuan, A. T. (2013) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2013.07.008 · Cited by 73
Zhu, B., Ma, A., Yang, L., & Dang, X. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141224476 · Cited by 69
Mirabelli, C. K., Ting, A., Huang, C.-H., Mong, S., & Crooke, S. T. (1982) · PubMed · Cited by 68
Interleukin-22 Inhibits Bleomycin-Induced Pulmonary Fibrosis
Liang, M., Wang, J., Chu, H., Zhu, X., He, H., Liu, Q., Qiu, J., Zhou, X., Guan, M., Xue, Y., et al. (2013) · Mediators of Inflammation · doi:10.1155/2013/209179 · Cited by 59
Antiflammin-1 attenuates bleomycin-induced pulmonary fibrosis in mice
Liu, W. Y., Wan, J., Han, J., Li, C., Feng, D., Yue, S., Huang, Y., Chen, Y., Cheng, Q., Li, Y., et al. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-101 · Cited by 53
Moeller, A., Rodriguez-Lecompte, J. C., Wang, L., Gauldie, J., & Kolb, M. R. J. (2006) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2006.09.006 · Cited by 42
Ruehl, M., Muche, M., Freise, C., Erben, U., Neumann, U. P., Schuppan, D., Popov, Y. V., Dieterich, W., Zeitz, M., Farndale, R. W., et al. (2011) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-4-1 · Cited by 39
Protective and Therapeutic Effect of Molsidomine on Bleomycin-Induced Lung Fibrosis in Rats
Kılıç, T., Parlakpınar, H., Polat, A., Taşlıdere, E., Vardı, N., Sarihan, M. E., Ermis, H., & Tanbek, K. (2014) · Inflammation · doi:10.1007/s10753-014-9841-1 · Cited by 38
LUNG FIBROSIS INDUCED BY BLEOMYCIN: STRUCTURAL CHANGES AND OVERVIEW OF RECENT ADVANCES
Grande, N. R., Sá, C., & Águas, A. P. (1998) · Cited by 38
Current and novel drug therapies for idiopathic pulmonary fibrosis
Adamali, H. I., & Maher, T. M. (2012) · Dove Medical Press (Taylor and Francis Group) · Cited by 28
Uesugi, S., Shida, T., Ikehara, M., Kobayashi, Y., & Kyogoku, Y. (1984) · Nucleic Acids Research · doi:10.1093/nar/12.3.1581 · Cited by 26
Recent Evidence for Pharmacological Treatment of Idiopathic Pulmonary Fibrosis
Covvey, J. R., & Mancl, E. E. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014551015 · Cited by 20
Recent Advances in Idiopathic Pulmonary Fibrosis
Park, S. H., & Lee, E. J. (2013) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2013.74.1.1 · Cited by 19
Modelos experimentales para el estudio de la fibrosis pulmonar: utilidad práctica actual y futura
Molina‐Molina, M., Pereda, J., & Xaubet, A. (2007) · Archivos de Bronconeumología · doi:10.1157/13109471 · Cited by 18
Experimental Models for the Study of Pulmonary Fibrosis: Current Usefulness and Future Promise
Molina‐Molina, M., Pereda, J., & Xaubet, A. (2007) · Archivos de Bronconeumología · doi:10.1016/s1579-2129(07)60115-3 · Cited by 17
Cited by
Xing, L., Zhang, H., Qi, R., Tsao, R., & Mine, Y. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b06146 · Cited by 543
Vieira, D., & Gamarra, L. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s117210 · Cited by 427
Antar, S. A., Ashour, N. A., Marawan, M. E., & Al-Karmalawy, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044004 · Cited by 366
The Bleomycin Model of Pulmonary Fibrosis
Liu, T., De Los Santos, F. G., & Phan, S. H. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7113-8_2 · Cited by 357
The Role of Macrophages in the Development of Acute and Chronic Inflammatory Lung Diseases
Lee, J.-W., Chun, W., Lee, H. J., Min, J.-H., Kim, S.-M., Seo, J.-Y., Ahn, K.-S., & Oh, S.-R. (2021) · Cells · doi:10.3390/cells10040897 · Cited by 291
Metadata
- Authors
- Della Latta, V., Cecchettini, A., Del Ry, S., & Morales, M. A.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 97
- Pages
- 122-130
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W296319558
- Cited by
- 514
- References
- 65
- FWCI
- 21.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.